Firalis launches its Healthy Volunteer Clinical Study (HVCS)
Firalis SAS, sponsor of HVCS, welcomed its first volunteer on June 18, 2025. The study tests biomarker stability in blood, urine, saliva and buccal cells.
Media: Press releases
ONCOSCREEN partners meet in Kaunas to advance risk-based colorectal cancer screening
The European project held its second plenary meeting in Kaunas, Lithuania. Firalis leads biomarker identification and the clinical trial work.
Firalis joins VOLABIOS, a European project on the early diagnosis of schizophrenia
VOLABIOS started on January 1, 2025 with 18 partners from 11 European countries. Firalis contributes biomarker validation and its biobank.
Firalis obtains ISO 14001 environmental certification
Firalis SAS is certified ISO 14001 for the development, production and sale of in vitro diagnostic tests, and for the storage and analysis of samples.
Firalis and Celemics launch FiMICS®, a panel of cardiac-enriched long non-coding RNAs
Developed with Celemics and the Cardiolinc™ network, the FiMICS® research panel quantifies more than 3,200 cardiac-enriched lncRNAs in peripheral blood.
Firalis launches BIOPRED, a targeted mRNA panel for inflammatory and autoimmune disorders
The BIOPRED research panel profiles over 2,100 inflammatory-pathway mRNAs from whole blood without RNA extraction, building on BT-Cure and RABIOPRED.
HeartLiNC: a programme led by Firalis to predict heart failure after myocardial infarction
HeartLiNC brings Firalis together with Seoul National University Hospital, QuantaMatrix, CHU de Toulouse and SimplicityBio.
Media enquiries